Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) Equity Average (2016 - 2026)

Tandem Diabetes Care filings provide 12 years of Equity Average readings, the most recent being $144.1 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 42.47% to $144.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $144.1 million, a 42.47% decrease, with the full-year FY2025 number at $209.1 million, down 27.48% from a year prior.
  • Equity Average hit $144.1 million in Q4 2025 for Tandem Diabetes Care, up from $133.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $443.5 million in Q2 2022 to a low of $133.1 million in Q3 2025.
  • Median Equity Average over the past 5 years was $325.7 million (2021), compared with a mean of $309.3 million.
  • Biggest five-year swings in Equity Average: surged 69.02% in 2021 and later crashed 43.54% in 2025.
  • Tandem Diabetes Care's Equity Average stood at $411.4 million in 2021, then increased by 4.74% to $430.9 million in 2022, then dropped by 27.17% to $313.8 million in 2023, then fell by 20.21% to $250.4 million in 2024, then plummeted by 42.47% to $144.1 million in 2025.
  • The last three reported values for Equity Average were $144.1 million (Q4 2025), $133.1 million (Q3 2025), and $144.3 million (Q2 2025) per Business Quant data.